Home care deserves a fair try before PRP made from your spun blood

Steady movement can make daily use easier

Regular exercise can strengthen the muscles that steady your knee. Begin gently enough that the joint isn't stirred up for days. Two shorter walks may suit you better than one long walk during a flare, and you can add time later.

A well-fitted brace or cane may help during errands and longer days. If body weight strains the knee, a small change can help without blame or lectures. Heat or cold may feel good for a while, and your clinician can match these choices to the cause.

QC Kinetix can discuss care that doesn't involve surgery

When home care hasn't done enough, QC Kinetix can look over the joint and discuss PRP. PRP means platelet-rich plasma: the clinic separates your blood by spinning it, then prepares plasma holding extra clot-making platelets for the sore knee during an office visit. The clinic may call it concentrated PRP because the prepared plasma holds more platelets than your usual blood. It won't suit every knee.

Ask whether white blood cells remain in the plasma and why the office uses that method; you'll also want the expected visits, full cost, and advice for walking and work afterward. Research hasn't settled one best way to prepare PRP, so don't agree to more visits without a clear reason.

A badly worn knee may need a surgery discussion

A badly worn knee may not get enough relief from PRP or home care. A surgical opinion can give you useful facts without signing you up for surgery. You'll learn what recovery may take and what waiting may mean, while the choice remains yours.

A hot knee or a major injury needs faster medical care, as does a leg that buckles and won't hold you up when you stand. Those problems need the cause checked before you weigh paid options. Safety comes first.

Sources

1. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis contains 29 recommendations, and the work group explicitly identified intra-articular corticosteroid, hyaluronic acid AND platelet-rich plasma as areas needing better research - including osteoarthritis characterisation, severity stratification, clinically relevant outcomes with controls for bias, and cost-effectiveness analysis. PRP is presented as an open research question in this guideline, not as a settled treatment.

   Brophy RH, Fillingham YA — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

3. A Bayesian network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 trials, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, the effects of 16 of the 18 intra-articular interventions in knee or hip OA were smaller than the minimal clinically important difference and most were consistent with placebo effects; triamcinolone had the highest probability of exceeding the MID at weeks 2-6.

   Pereira TV, Saadat P, Bobos P, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

4. A meta-analysis of eight studies (648 patients, mean age 59) judged at low risk of bias found PRP significantly better than intra-articular corticosteroid for knee OA symptoms at 3, 6 and 9 months (P<0.01), with the largest effects at 6 months (SMD -0.78; 95% CI -1.34 to -0.23) and 9 months (SMD -1.63; 95% CI -2.14 to -1.12). This is the strongest available case for PRP as a longer-acting alternative to a steroid shot.

   McLarnon M, Heron N — Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis. BMC Musculoskeletal Disorders, 2021. DOI: 10.1186/s12891-021-04308-3.

5. A network meta-analysis of 79 randomized trials with 8761 patients compared 11 injectable options for knee osteoarthritis. At 4-6 weeks and 3 months the highest-ranked treatment for WOMAC was high-molecular-weight hyaluronic acid plus corticosteroid; at 6 months the highest-ranked treatment for WOMAC was PRP. Stromal vascular fraction ranked highest for VAS at all time points, on a much thinner evidence base.

   Anil U, Markus DH, Hurley ET, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. The Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

6. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

7. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

8. A meta-analysis of 34 randomized trials (1403 PRP knees, 1426 control knees) found WOMAC favoured PRP over placebo at 12 months (P=.02) and over hyaluronic acid at 6 and 12 months (P<.001), and favoured PRP over steroids on VAS pain and KOOS at 6 months. Critically, the authors reported that the superiority of PRP did NOT reach the minimal clinically important difference for any outcome, and graded the quality of evidence as low.

   Filardo G, Previtali D, Napoli F, et al. — PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Cartilage, 2021. DOI: 10.1177/1947603520931170.

9. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

10. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

    Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.